VMK Medical Enterprises Pharmaceutical Import Profile — Seychelles (DGFT 2022–2026)

Name: VMK Medical Enterprises Pharmaceutical Import Records from India — 4 Products, $102.8K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

VMK Medical Enterprises — Pharmaceutical Importer Profile (2026) | 4 Products, $102.8K Trade | TransData Nexus

VMK Medical Enterprises

Pharmaceutical Importer · Seychelles · Brand Names & OTC Products Focus · $102.8K Total Trade · DGFT Verified

VMK Medical Enterprises is a pharmaceutical importer based in Seychelles with a total trade value of $102.8K across 4 products in 1 therapeutic categories. Based on 18 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. VMK Medical Enterprises sources from 3 verified Indian suppliers, with Capstone Export & Import accounting for 99.4% of imports.

VMK Medical Enterprises — Import Portfolio & Supplier Network

VMK Medical Enterprises import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to VMK Medical Enterprises?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Capstone Export & Import	$9.6M	2,703	99.4%
Capstone Export Import	$47.7K	527	0.5%
Sayar Life-care	$11.9K	111

What Formulations Does VMK Medical Enterprises Import?

Formulation	Value	Ships
Zoclar 500MG tabs (4's)	$411.1K	17
Augmentin 625MG (10's)	$297.9K	15
Gasex tabs (100's)	$246.9K	17
Cystone tabs (60's)	$216.1K	18
Strepsils orange lozanges(224's)	$196.1K	17
Itrasys 200MG tabs (4's)	$195.2K	15
Digene gel mint syp (200ML)	$176.7K	18
Dorzox-t eye drops (5ML)	$166.5K	9
Ascoril ls syp (100ML)	$154.2K	18
Alphagan 0.2 eye drops (5ML)	$145.9K	9
Pilex tabs (60's)	$143.9K	16
Volini spray (60GM)	$143.8K	15
Augmentin dds syp (30ML)	$142.0K	10
Dorzox eye drops (5ML)	$133.9K	12
Cremaffin plus syp (225ML)	$133.6K	15

VMK Medical Enterprises imports 929 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Betadine	Brand Names & OTC Products	$76.1K	9	1.0%	15
2	Soframycin	Brand Names & OTC Products	$18.5K	3	3.1%	5
3	Neosporin	Brand Names & OTC Products	$4.1K	3	4.1%	3
4	Combiflam	Brand Names & OTC Products	$4.1K	3	16.9%	2

VMK Medical Enterprises imports 4 pharmaceutical products across 1 categories into Seychelles totaling $102.8K.

VMK Medical Enterprises — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

VMK Medical Enterprises is a pharmaceutical importer based in Victoria, Seychelles. The company specializes in sourcing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. With a total import value of $103,000 USD across 18 shipments from 2022 to 2026, VMK Medical Enterprises plays a significant role in the Seychelles pharmaceutical distribution network. The company's portfolio is highly concentrated, with its top five products accounting for 100% of its imports. This indicates a focused approach to meeting specific market demands within the Seychelles healthcare sector.

2Distribution Network

VMK Medical Enterprises operates from its headquarters in Victoria, the capital city of Seychelles. While specific details about its warehouse locations and logistics capabilities are not publicly disclosed, the company's consistent import activity suggests a well-established distribution network within the country. Given the limited geographic size of Seychelles, it is likely that the company has centralized its operations to efficiently serve the local market. However, without explicit information, it is challenging to assess the extent of its geographic coverage beyond the main islands.

3Industry Role

In the Seychelles pharmaceutical supply chain, VMK Medical Enterprises functions primarily as a wholesaler and distributor. By importing a diverse range of finished pharmaceutical products from India, the company ensures the availability of essential medications in the local market. Its role is crucial in bridging the gap between international manufacturers and local healthcare providers, thereby contributing to the overall health infrastructure of Seychelles.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — VMK Medical Enterprises

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

VMK Medical Enterprises exhibits a high degree of supplier concentration, with 99.4% of its imports sourced from CAPSTONE EXPORT & IMPORT. This single-source dependency could pose risks, such as supply chain disruptions or price fluctuations. However, the company's consistent import activity from this supplier over multiple years suggests a stable and reliable relationship. The absence of significant imports from other suppliers indicates that VMK Medical Enterprises has strategically chosen to concentrate its sourcing to maintain quality control and streamline operations.

2Supply Chain Resilience

The resilience of VMK Medical Enterprises's supply chain is closely tied to its reliance on CAPSTONE EXPORT & IMPORT. While this concentrated sourcing strategy may enhance operational efficiency, it also exposes the company to potential risks associated with supply chain disruptions. The company's import data indicates a diverse range of formulations, suggesting that it has access to a broad spectrum of products. However, the lack of publicly available information about backup suppliers and shipping routes makes it difficult to fully assess the company's supply chain resilience. Additionally, without specific details on the regulatory compliance of CAPSTONE EXPORT & IMPORT, it is challenging to evaluate the robustness of the supply chain from a compliance perspective.

Importing Pharmaceuticals into Seychelles — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Seychelles

1Regulatory Authority & Framework

In Seychelles, the Ministry of Health oversees the regulation of pharmaceutical imports. Importers must obtain an import license from the Ministry of Health through the Import and Export Unit of the Trade Division of the Ministry of Finance, Economic Planning, and Trade. This process acts as a one-stop shop for processing these applications and is a facilitator in the whole process of obtaining the license. The Medical Information Unit, Pharmaceutical Services of the Ministry of Health, is responsible for approving pharmaceutical and veterinary products. This regulatory framework ensures that imported pharmaceutical products meet the necessary standards for safety and efficacy before entering the Seychelles market.

2Import Licensing & GMP

Importers of pharmaceutical products into Seychelles are required to obtain an import license from the Ministry of Health. This license is essential for the legal importation and distribution of pharmaceutical goods within the country. Regarding Good Manufacturing Practice (GMP) certifications, Seychelles recognizes standards such as EU GMP, WHO GMP, and PIC/S. Importers must ensure that their suppliers hold valid GMP certificates from recognized authorities to comply with Seychelles' import regulations. Additionally, wholesale distribution authorization is mandatory for entities involved in the distribution of pharmaceutical products, ensuring that they adhere to the required standards and regulations.

VMK Medical Enterprises — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

VMK Medical Enterprises's product strategy focuses on a narrow range of therapeutic categories, importing primarily brand-name and over-the-counter (OTC) products. This focus suggests a strategic decision to cater to specific market demands within Seychelles, possibly targeting common health conditions that require readily available treatments. The market demand for these products is likely driven by the prevalence of certain health issues and the consumer preference for established brands. By concentrating on these areas, VMK Medical Enterprises aims to meet the immediate healthcare needs of the population effectively.

2Sourcing Profile

VMK Medical Enterprises's sourcing strategy is heavily reliant on generic drug imports, with a preference for formulations that are widely used and recognized. India's pharmaceutical industry, known for its large-scale production of generic drugs, aligns well with the company's procurement needs. This sourcing approach allows VMK Medical Enterprises to offer cost-effective solutions to the Seychelles market while maintaining a focus on quality and reliability.

3Market Positioning

Seller's Guide — How to Become a Supplier to VMK Medical Enterprises

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with VMK Medical Enterprises, given the company's focused product strategy and reliance on a single supplier. Potential gaps in VMK Medical Enterprises's current sourcing include the need for diversification in product offerings and the introduction of new therapeutic categories to meet evolving market demands. Indian exporters can leverage these opportunities by offering high-quality products that align with VMK Medical Enterprises's strategic focus and by ensuring compliance with Seychelles' regulatory requirements.

2Requirements & Qualifications

Indian exporters aiming to supply VMK Medical Enterprises must ensure that their products meet Seychelles' regulatory standards, including holding valid GMP certificates from recognized authorities such as the EU, WHO, or PIC/S. Products must undergo batch testing and meet stability requirements. Labeling must be in English and include all necessary information as mandated by the Ministry of Health. Additionally, exporters should be prepared to navigate the import licensing process, ensuring that all necessary approvals are obtained for their products to enter the Seychelles market.

How to Approach

Frequently Asked Questions — VMK Medical Enterprises

What products does VMK Medical Enterprises import from India?

VMK Medical Enterprises imports 4 pharmaceutical products across 1 categories. Top imports: Betadine ($76.1K), Soframycin ($18.5K), Neosporin ($4.1K), Combiflam ($4.1K).

Who supplies pharmaceuticals to VMK Medical Enterprises from India?

VMK Medical Enterprises sources from 3 verified Indian suppliers. The primary supplier is Capstone Export & Import (99.4% of imports, $9.6M).

What is VMK Medical Enterprises's total pharmaceutical import value?

VMK Medical Enterprises's total pharmaceutical import value from India is $102.8K, based on 18 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does VMK Medical Enterprises focus on?

VMK Medical Enterprises imports across 1 categories. The largest: Brand Names & OTC Products (100.0%).

Get Full VMK Medical Enterprises Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.